ImmunoGen Reports Recent Progress and 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Immunogen (IMGN) Reports Q4 Loss of $0.17/sh
February 25, 2022 6:38 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.17), versus $0.16 reported last year. Revenue for the quarter came in at $28 million, versus $85.8 million reported last year.
GUIDANCE:
Immunogen sees 2022 revenue of $75-85 million.
revenues between $75 million and $85 million;operating expenses... More